TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01298609

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occipital Stimulation
Description: Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occipital Stimulation
Description: Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
Study: NCT03371225

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Exercise
Description: Participants will walk in a treadmill (as to keep at 10% within their baseline heart rate) for 30 minutes.
Study: NCT01298609

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Occipital Stimulation
Description: Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
Study: NCT02075840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
Study: NCT01094743

Intervention type: DEVICE
Group type: OTHER
Intervention: lotrafilcon B lens
Description: Silicon Hydrogel contact lens
Study: NCT01429961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1\~14
Study: NCT03033121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Study: NCT00970411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN951
Description: Orally once daily administration
Study: NCT01246648

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: dental extraction and gingival epithelial biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsy
Description: dental extraction and gingival epithelial biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: dental extraction and gingival epithelial biopsy
Study: NCT00839982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given SC
Study: NCT00003377

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin

Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel

Intervention type: RADIATION
Group type: OTHER
Intervention: brachytherapy

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study: NCT03675711

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Midline
Description: Patient will receive a Midline catheter within 48h after disappearance of indication for CVC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC
Description: Patient will receive a standard PVC within 48h after disappearance of indication for CVC
Study: NCT04541186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01878695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV/oral n-acetylcysteine
Study: NCT01536782

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bolus
Description: The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gravity
Description: The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump
Description: The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly.
Study: NCT02335021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: 2 packets per 12 fl oz

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: equisweet to sucralose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose + maltodextrin
Description: sucralose plus equicaloric (to sucrose) maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose + Sucrose
Description: half the amount of sucralose plus equicaloric sucrose
Study: NCT01341080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 1mg twice daily for eight weeks after a one week dose escalation period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 1mg twice daily for eight weeks after a one week dose escalation phase.
Study: NCT06204185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Locally delivered Metformin gel in the treatment of periodontitis patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel consist of drug without the active component.
Study: NCT02202356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02377219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hormonal and blood analysis
Study: NCT01209676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCgp100 injection
Description: a monoclonal T cell receptor anti-CD3scFv fusion protein
Study: NCT04437108

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Li-SWT (suprapubic approach)
Description: The patient will be asked to lie in flat dorsal position. A commercially used gel for sonography will be applied to the suprapubic region. The applicator will be placed on suprapubic region with two fingers apart from the symphysis pubis tilting to 45°. Shock waves will be directed to 3 different sites; the midline (over the bladder dome) and 3 cm right and left to the midline (over bilateral bladder walls). The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Li-SWT (perineal approach)
Description: The patient will be asked to lie in lithotomy position. A commercially used gel for sonography will be applied to the perineum. The applicator will be placed on perineal region. Shock waves will be directed to 3 different sites: the midline and 2 cm above and below the midline. The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Li-SWT (combined approach)
Description: The patient will receive 3000 shocks; 1500 shocks through suprapubic approach (500 shocks per site) and another 1500 shocks through perineal approach (500 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: The same technique of Li-SWT will be used but the applicator of the shock wave device will be turned off.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin
Description: The patients will be treated by antimuscarinics (solifenacin) which are considered as the conventional treatment of storage symptoms after prostatectomy.
Study: NCT01686932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: vildagliptin 50mg BID for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: vildagliptin 50mg BID for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: sitagliptin 100mg QD for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: sitagliptin 100mg QD for 8 weeks
Study: NCT01663337

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Description: CPT is a highly structured course of therapy that focuses primarily on the cognitive restructuring of trauma related beliefs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention (RP)
Description: RP utilizes high-risk situation assessment/avoidance, drink refusal skills, assertiveness training,cognitive restructuring as well as other approaches to address issues of alcohol use/dependance.
Study: NCT01941264

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: community based screening and treatment
Description: Already described in intervention arm description.
Study: NCT01287234

Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiogram/SonR
Description: All patients will have an echocardiograph and SonR sensor readings
Study: NCT04008862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partnership-based nursing practice
Description: Provided by clinical nurse specialists (n=2) and specialized nurses (n=3): i) Partnership-based theoretical nursing practice framework: Family involvement, living with symptoms and access to healthcare -primary goal of enhancement of the health experience. Key question: What are your main concerns about the health of the person with the lung disease? Followed by conversations: a) Existence of lung disease and symptoms that the patient has. b) Nature of disease, its management, quitting smoking, use of inhaler medications, utilization of health care, negative feelings and issues. Skills and motivation to undertake activities to maintain and improve well-being, skills in communication with family, relatives and health professionals. ii) Empirical knowledge about the nature of COPD, symptom management and palliative care and the GOLD clinical guidelines. iii) Patients are seen over an undefined time period in the out-patient clinic or at home depending on needs and capabilities.
Study: NCT04260022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascentage Pharma HQP1351 bioavailable inhibitor
Description: HQP1351 taken by mouth every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascentage Pharma HQP1351 bioavailable inhibitor
Description: HQP1351 taken by mouth every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascentage Pharma HQP1351 bioavailable inhibitor
Description: HQP1351 taken by mouth every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascentage Pharma HQP1351 bioavailable inhibitor
Description: HQP1351 taken by mouth every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Administered in all patients as a continuous IV infusion at the dosage of 28μg daily (9μg daily for Cycle 1 Day 1 to Day 7).
Study: NCT02558881

Intervention type: PROCEDURE
Intervention: Virtual colonoscopy

Intervention type: PROCEDURE
Intervention: Colon capsule
Study: NCT01280123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd~Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd~Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
Study: NCT01600131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver problem-solving
Description: This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
Study: NCT03328130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2/5-hPDE6B
Description: Subretinal administration in one eye

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2/5-hPDE6B
Description: Subretinal administration in one eye

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2/5-hPDE6B
Description: Subretinal administration in one eye

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2/5-hPDE6B
Description: Subretinal administration in one eye

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2/5-hPDE6B
Description: Subretinal administration in one eye
Study: NCT00720239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taliderm wound healing dressing
Description: Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taliderm wound healing dressing
Description: Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taliderm wound healing dressing
Description: Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase.
Study: NCT02713581

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Venous blood will be sampled for laboratory analyses (see outcomes).

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Venous blood will be sampled for laboratory analyses (see outcomes).
Study: NCT02206711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose of drug on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose of drug on Day 1
Study: NCT00406315

Intervention type: DRUG
Group type: OTHER
Intervention: ziprasidone
Description: Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
Study: NCT01671488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses. All 4 doses of ADXS11-001 will be 1x109 cfu.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: 10 mg/m2, day 1 and 29 (day 29 can be + 7 days)
Study: NCT02075840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
Study: NCT00544167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study: NCT01671488

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: 54 Gy in 30 fractions at 1.8 Gy per fraction.
Study: NCT00544167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study: NCT02118987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Study: NCT00022555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT01452074

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Training
Description: During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, \~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week

Intervention type: OTHER
Group type: OTHER
Intervention: Weight Loss with continued Exercise Training
Description: After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight
Study: NCT00271440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)
Study: NCT02371837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates and fall prevention
Description: A 2 days per week during 6 week Pilates practice will be performed in experimental group in order to check the effectiveness in fall prevention
Study: NCT01624805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV or PO
Study: NCT00271440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)
Study: NCT01624805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study: NCT04643470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match zanubrutinib
Study: NCT00812916

Intervention type: PROCEDURE
Intervention: RF ablation, using specialized CFAE software
Description: RF ablation
Study: NCT03755531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Heat stable Carbetocin, a clear colourless solution. Oxytocic activity: approximately 50 IU of oxytocin/vial. One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection, slowly over 1 minute after labor of the baby at once. It was used once and no further doses were given.~Drug was kept in cold storage (2 to 8°C).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, a clear colourless solution. One ml of oxytocin (10 IU), was given as a bolus intravenous injection over 1 minute, after labor of the baby at once. Further doses can be given accordingly.~Drug was kept in cold storage (2 to 8°C).